Navigation Links
VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
Date:8/1/2011

om this study will be used as part of the QNEXA New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA).

The Marketing Authorization Application (MAA) for QNEXA was submitted to the European Medicines Agency (EMA) in December 2010.  In May of 2011 we received the 120-day list of questions from the Committee for Medicinal Products for Human Use (CHMP) and began preparing our response.  The questions and issues raised by the CHMP were consistent with those raised by the FDA.  We have requested and have been granted a meeting with the rapporteur September 2011 to discuss the 120-day questions.  The purpose of this meeting is to provide clarification to certain questions to assist us in preparing our response.  Our response to the 120-day questions is expected in the fourth quarter of 2011.

"The FORTRESS protocol has been reviewed and approved by the FDA.  The results of the retrospective study announced in July 2011 and Danish study published in the May 2011 issue of the Journal of the American Medical Association both concluded that topiramate was not a major teratogen. We look forward to the FORTRESS results and resubmission of the QNEXA NDA in the fourth quarter of 2011," stated Peter Tam, president of VIVUS.

Avanafil UpdateIn June 2011, we submitted an NDA to the FDA seeking approval of avanafil, our investigational drug for the treatment of erectile dysfunction (ED). The NDA submission follows the successful completion of an extensive phase 3 program for avanafil, which included over 1,350 patients, where avanafil was shown to be well tolerated and effective in treating men with ED.

"The highlight of the second quarter was the filing of the NDA for avanafil.  Congratulations to all of the members of the avanafil development team who worked diligently to achieve this significant corporate milestone.  In a large and growing market, avanafil, if approved, shou
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
2. VIVUS to Present at Three Upcoming Investor Conferences in March
3. VIVUS Provides Regulatory Update on QNEXA NDA
4. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. VIVUS to Present at Two Upcoming Investor Conferences
7. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
8. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
9. VIVUS Announces Sale of MUSE Assets to Meda
10. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
11. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... , HAMBURG , Feb. 3 ... Wound Therapy (NPWT) will assemble this week to develop a ... NPWT Expert Panel is drafting recommendations for a range of ... published clinical evidence.  Where published evidence is insufficient, the Panel ...
... Feb. 2 Celsis In Vitro, Inc. (Celsis IVT) ... XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. ... Illinois in Chicago .  XenoTech and Sekisui Medical ... processes and methods performed by XenoTech associated with its in ...
Cached Medicine Technology:International NPWT Expert Panel Convenes in Hamburg 2International NPWT Expert Panel Convenes in Hamburg 3Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
(Date:9/2/2014)... September 03, 2014 Recently, Top ... hosting companies and announced that JustHost ( http://www.justhost.com/track/seohosts ... the webmasters. , “The hosting suppliers we recommend ... their competitors on hosting features, uptime and server ... 10 Best SEO Hosting says. “We believe that ...
(Date:9/2/2014)... TCG, a leading government technology strategy and ... of the fastest-growing companies in America for the seventh year ... previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, and ... 86% from 2010 to 2013, ranking the company at position ... America - up 635 spots from 2013! More information is ...
(Date:9/2/2014)... Cloud Medical Doctor Software Corporation (Cloud-MDs) ... Practice Business Operations solutions and Billing Services for the ... solutions for all industries announced today that its CEO ... of the CME in Chicago by PRICE Futures Group ... are very proud of the recognition that our CipherLoc ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The Wm. Jennings ... fair and public town hall meeting for Veterans and their ... at the outreach fair to provide Veterans with valuable healthcare ... “The town hall will provide a forum where we can ... programs.” , The outreach fair will be held 4:45 p.m. ...
(Date:9/2/2014)... -- Complications are rare among breast cancer patients ... indicates. However, the researchers did find that ... higher risk for certain complications than a single ... breast cancer patients who had a single (64 ... and were followed for 30 days after surgery. ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2
... and $13.5 Billion in Economic ActivitySACRAMENTO, Calif., April 7 ... part of the state,s economy, generating 130,000 jobs and ... a report released today by the California ... the Taylor Feldman Group, an outside consulting firm with ...
... tied to a retinal disorder, study finds , , TUESDAY, ... drugs called glitazones are associated with an increased risk ... which features swelling and fluid accumulation in the retina. ... that includes medicines such as pioglitazone (Actos) and rosiglitazone ...
... the opinions of African American employees GAITHERSBURG, Md., April 7 ... food and facilities management services company, "allows me to be ... a woman and have a voice in the company," said ... for Health Care Services and chair of the African American ...
... ST. LOUIS, Missouri, April 7 , ... Testing and Remediation Product Suite , ... scientific, technical and,medical information products and services, announced ... Software, Inc. (PDS), the provider of,Softwarefornurses.com online learning ...
... MedPredict,s Rheumatology Thought Leader Panel Creates a ... MedPredict Market Research, a global provider ... has published a new report providing critical ... in the market for rheumatology therapies, including ...
... IL, April 7, 2009) Managing pain in the ICU ... team. However, new reports suggest that taking a comprehensive approach ... in the ICU and even decreasing the incidence of preventable ... CHEST , the peer-reviewed journal of the American College of ...
Cached Medicine News:Health News:California Health Plans Vital to State's Economy 2Health News:Certain Diabetes Drugs May Pose Eye Risk 2Health News:Sodexo Named as One of the Top Three Companies for African Americans on 2009 DiversityInc Top Ten Companies List 2Health News:Elsevier Acquires Professional Development Software, Inc., Provider of 'Software for Nurses' Online Learning Education 2Health News:New Report Defines Challenges for New Entrants in Key Rheumatology Markets 2Health News:'Pain in the ICU' report suggests comprehensive approach 2Health News:'Pain in the ICU' report suggests comprehensive approach 3
Forceps, delicate, straight....
Jewelers Forceps, standard, straight....
1 mm x 6 mm oval hole....
Jewelers forceps. Insulated....
Medicine Products: